CAS: 578-74-5; 5-Hydroxy-2-(4-Hydroxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-4H-Chromen-4-One

上下游产品

CAS号520-36-5 芹菜素; 芹黄素; 5,7,4... | CAS号50-99-7 D(+)-无水葡萄糖 | CAS号2280-44-6 D-glucopyranose

📜柚皮苷置于吡啶,硫酸,5%-Palladium/activated Carbon,四丁基溴化铵,水,氢气,碘,Potassium Carbonate,Ammonium Hydroxide体系中,用 甲醇,乙醇,氯仿,乙酸乙酯,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 36.0H,反应生成 芹甙元-7-葡萄糖苷
参考文献:柚皮苷中芹菜素和acacetin-7-O-β-D-糖苷的半合成及其细胞毒活性
标题:柚皮苷中芹菜素和acacetin-7-O-β-D-糖苷的半合成及其细胞毒活性
摘要:芹菜素-7-O-β-D-糖苷1-8和acacetin-7-O-β-D-糖苷9-16由4'-O-苄基芹菜素17和acacetin 18通过糖苷化和相应的脱保护作用而半合成分别是α-乙酰基糖基溴化物.化合物17和18是通过碘化,随后碱诱导的消除,4'-O-苄基化或4'-O-甲基化以及使用柚皮苷作为起始原料的酸水解制备的,所述柚皮苷为容易获得且廉价的原料.通过标准mtt方法评估了它们对五种人类癌细胞系(hl-60,Smmc-7721,A-549,Mcf-7和sw480)的细胞毒性潜力.结果表明,化合物2,9和19对hl-60,Smmc-7721,A-549,Mcf-7和sw480表现出中等的细胞毒性,而化合物3对mcf-7选择性表现出有效的细胞毒性.在合成的目标化合物中,有3,4,7,11
DOI:10.1016/j.Carres.2012.05.013

专利信息

专利号:US-2002165207-A1
优先权日:2001-05-02
标题 :Compositions and methods for the treatment of diabetic neuropathy
发明人：ROSENBLOOM RICHARD
摘要:Compositions and a method for the treatment of diabetic neuropathy is disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.

专利号:US-7914823-B2
优先权日:2000-12-21
标题 :Method and composition for the topical treatment of diabetic neuropathy
发明人：ROSENBLOOM RICHARD ALLEN
权利人:PROPHASE LABS INC
摘要:A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recovery of the damaged nerve tissues.

专利号:US-2024010871-A1
优先权日:2022-07-06
标 题:Photocatalytic coating agent, photocatalytic film, display device, and binder synthesis method
发明人：KAWAI HIDETSUGU; IKARI MASAFUMI; MORIMOTO MASAO; SHIBAI YASUHIRO
权利人:SHARP KK
摘要:A photocatalytic coating agent of the present disclosure includes a liquid medium, photocatalyst particles, and a binder, in which the binder is a hydrolysis condensate of a tetraalkoxysilane and is a long-chain siloxane compound.

专利号:EP-1493431-B1
优先权日:2003-07-03
标题:Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions
发明人：WIRTH CORINNA DR; BUCHHOLZ HERWIG DR
权利人:MERCK PATENT GMBH
摘要:Use of an aqueous or aqueous-alcoholic extract (A) of Bauhinia is claimed to make a composition for cosmetic or pharmaceutical treatment of skin and hair. Use of an aqueous or aqueous-alcoholic extract (A) of Bauhinia is claimed to make a composition for: (a) care, preservation or improvement of the general condition of the skin or hair; (b) prevention and/or inhibition of the aging process for human skin or hair; (c) for promoting healing of wounds; (d) for prevention and/or treatment of skin diseases associated with abnormal keratinization, and (e) for prevention and/or treatment of all malignant or benign growths of the dermis or epidermis. An independent claim is also included for a composition containing (A). ACTIVITY : Dermatological; Vulnerary; Antiseborrheic; Antipsoriatic; Cytostatic; Antiinflammatory; Virucide. MECHANISM OF ACTION : Protein glycosylation inhibitor. In a test, human fibroblasts were cultured in the presence of Vitamin C to stimulate collagen synthesis, then lysed and labeled with tritiated glucose for 15 days, Proteins were removed, extraction and precipitation were carried and the amount of bound glucose measured by liquid scintillation counting. Addition of an aqueous-alcoholic extract of Bauhinia fortificata (0.03 mg/ml), reduced protein glycosylation to 55% of that in a control.

专利号:WO-2006042625-A2
优先权日:2004-10-15
标 题 :Compositions with inhibitors of the synthesis of prostaglandin and/or of leukotriene in conjunction with stimulators of the release of cutaneous neuromediators

专利号:EP-1799311-A2
优先权日:2004-10-15
标 题:Compositions with inhibitors of the synthesis of prostaglandin and/or of leukotriene in conjunction with stimulators of the release of cutaneous neuromediators